This was an open-label, single-center study to evaluate the usability of abaloparatide-sMTS by participants with low BMD.

This study aimed to evaluate the ability of participants to self-administer 300 μg abaloparatide-sMTS over a period of 29 days based on PK and PD markers.

Inclusion Criteria:

• Postmenopausal for at least 2 years
• BMD T-score based on the female reference range <-1.0 and >-5.0 at the lumbar spine (L1-L4) or hip (femoral neck or total hip) by dual energy X-ray absorptiometry (DXA)
• Good general health as determined by medical history and physical exam (including vital signs, and has a body mass index up to 33 kilograms/square meter (kg/m^2)
• Laboratory tests within the normal range including serum calcium (albumin-corrected), intact parathyroid hormone (PTH), serum phosphorus, alkaline phosphatase, and thyroid stimulating hormone
• Serum 25-hydroxyvitamin D values ≥ 20 nanograms per milliliter (ng/mL)

Exclusion Criteria:

• History of prior external beam or implant radiation therapy involving the skeleton, other than radioiodine
• History of bone disorders other than postmenopausal osteoporosis (such as Paget's disease)
• History of cancer within the last 5 years (with the exception of basal cell or squamous cancer of the skin)
• History of Cushing's disease, hypo or hyperparathyroidism, or malabsorptive syndromes within the past year
• Prior treatment with PTH, PTH-related peptide-derived drugs, or bone anabolic steroids, including abaloparatide, teriparatide, or PTH (1-84)
• Prior treatment with intravenous bisphosphonates at any time or oral bisphosphonates within the past year (12 months). Participants who have received a short course of oral bisphosphonate therapy (3 months or less) may be enrolled as long as the treatment occurred 6 or more months prior to enrollment
• Prior treatment with an investigational drug or device within the past 3 months or 5 half-lives of the investigational drug, whichever is longer